




The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Erratum

Erratum in «High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil»

José Ernesto Vidal^{a,b,*}, Alice Tung Wan Song^a, Maria Laura Matos^a, Daniel Bartmann^a, Guilherme dos Anjos^a, Ériqúe José Peixoto de Miranda^a, Ângela Carvalho Freitas^a, Mirian de Freitas Dalben^a, Claudinei Santana^c, Aluísio Cotrim Segurado^a, Cláudia Cortese Barreto^{d,e} Adrián Vladimir Hernández^f

^a Department of Infectious Diseases, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil

^b Department of Infectious Diseases, Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil

^c Pharmacy School, Universidade de São Paulo, São Paulo, SP, Brazil

^d Pro-Blood Foundation/Blood Center of São Paulo (FPS/HSP), Medical School, Universidade de São Paulo, São Paulo, SP, Brazil

^e Laboratory of Medical Investigation in Dermatology and Immunodeficiencies – LIM-56, Department of Dermatology, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil

^f Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, USA

In the article “High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil”, published in *Braz J Infect Dis.* 2013 Feb;17(1):41-7, please consider the following corrections:

Page 43, Table 1, line 18, “Previous use of NRTI, NNRTI and PIs: 87 (95)” should read as “Previous use of NRTI, NNRTI and PIs: 92 (100%)”.

Page 43, Results section, lines 28-31, “Tenofovir was the most frequent NRTI used (n = 83, 90.2%) and its genotyping evaluation were: sensitive: 16 (17.4%), intermediate resistance: 8 (8.7%), and resistance: 68 (73.9%).” should read as “All patients received lamivudine and their genotyping evaluation were resistant in all cases. Tenofovir was the second most frequent NRTI used (n = 83, 90.2%) and its genotyping evaluation were: sensitive:14 (16.9%), intermediate resistance: 7 (8.4%), and resistance: 62 (74.7%).”

DOI of original article: <http://dx.doi.org/10.1016/j.bjid.2012.08.022>.

* Corresponding author: Department of Infectious Diseases, Instituto de Infectologia Emílio Ribas, Avenida Doutor Arnaldo, Cerqueira, César, São Paulo, SP, 01246-000, Brazil. Tel.: +55 11 38961200; fax: +55 11 38961200.

E-mail address: josevibe@gmail.com (J. Ernesto Vidal).

1413-8670/\$ – see front matter

<http://dx.doi.org/10.1016/j.bjid.2013.05.001>